Nitric oxide (NO) is the principal vasoactive substance produced by the vascular endothelium with antitrombotic, antiatherogenic and vasodilator actions. The loss of these functions is now known as endothelial dysfunction (ED) and it has been proposed that it is the final common pathway in cardiovascular disease. At the moment there is an important body of evidence that supports the proposal that ED is a consequence of an imbalance between the free radicals, NO, superoxide (O 
Introduction
The endothelium plays a critical role in vascular homeostasis by controlling vascular tone, growth, and interaction of the vessel wall with platelets and leukocytes, through the secretion of powerful vasoactive substances such as prostacyclin and nitric oxide (NO). 1, 2 NO is synthesised from Larginine by action of the enzymes NO synthases and is rapidly metabolised to nitrite and nitrate.
1 Also NO is inactivated by the reaction with superoxide (O − 2 ) to form peroxynitrate (ONOO − ). This rapid reaction is limited only by the concentration of O − 2 . ONOO − is a potent vasoconstrictor, platelet proaggregant and prothrombotic 3 and it has been related with endothelial dysfunction (ED), which is the result of the interaction of different well known cardiovascular risk factors as hyperlipidaemia, diabetes mellitus, hypertension, obesity and smoking.
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Mechanism of endothelial dysfunction
The impaired biological activity of NO is one of the most characteristic factors of ED which leads to reduced vascular relaxation, increased platelet aggregation, increased leukocyte adhesion, and migration and proliferation of smooth muscle cells. 8 An impaired endothelial NO synthase gene expression, or accumulation of the endogenous inhibitor of NO synthase, asymmetrical N G -N Gdymethyl-L-arginine (ADMA), or a decreased activity of the normally expressed enzyme have been the mechanisms proposed of decreased NO production. 9, 10 Also important is the accelerated inactivation of NO by O Recently we proposed 12 that inappropriate diet and infection-inflammation may act as triggers to create the imbalance between the free radicals. Increased concentrations of oxidised low-density lipoprotein (LDL), owing to high intake of fat and low intake of antioxidants, produce both decreased NO and increased O − 2 endothelial synthesis, by accumulation of ADMA, due to reduced activity of the enzyme N G , N G -dimethylarginine dimethylaminohydrolase, and by activation of NAD(P)H oxidase. On the other hand, acute or chronic infectioninflammation stimulate higher circulating levels of proinflammatory cytokines, such as tumor necrosis factor alpha, interleukin 1 and interleukin 6. These Endothelial enzymes new therapeutic targets P López-Jaramillo and JP Casas S101 cytokines also contribute to reduced endothelial production of NO and to increase the generation of O − 2 , through the same mechanisms described for oxidised LDL. The net result of the imbalance in the production of NO and O − 2 is an increased generation of ONOO − , situations that convert the endothelium in a proatherogenic, prothrombotic and vasoconstrictor cell. 12 Moreover, globalisation of nutritional behaviour (energy-dense foods, poor in dietary fibre and several micronutrients) is contributing to an increased prevalence of lipid disorders. 13 Dyslipidaemias have been associated with alterations in NO bioavailibility, as a consequence of inactivation of NO by O 14 that up-regulate NAD(P)H oxidase activity. 15 According to this proposal, it was demonstrated that acute infections and the resulting inflammation might impair the function of vascular endothelium. 16 It is known that pro-inflammatory cytokines in concentration similar to that observed during infection and/or inflammation, induce production and release of O − 2 in endothelial cells through the activation of the NAD(P)H oxidase. 17 Recently, Hingorani et al, 18 showed how in healthy volunteers vaccinated with Typhoid vaccine, who developed an inflammatory response and cytokinaemia, the endothelial function was impaired. In our population we observed that C-reactive protein, which is associated with ED, 19 is an independent risk factor for essential hypertension. 20 Therefore, both classical and emergent risk factors, alter the endothelial function by produce an imbalance in endothelial synthesis of NO, O 
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Therapeutic approach to improve endothelial dysfunction
Based on the proposal above, the resulting prime aim was to get a therapeutic tool to restore the imbalance between NO and O − 2 . Over the last two decades it has been clearly demonstrated that the angiotensin-converting enzyme (ACE) inhibitors are highly effective against a variety of cardiovascular disorders. 21 Vanhoutte et al 22 demonstrated the beneficial effect of ACE inhibition on endothelial function in animal models. Mancini et al 23 demonstrated for the first time in humans that quinapril, an ACE inhibitor with the highest affinity by the tissular ACE, improved coronary endothelium-dependent vasodilation in patients with coronary artery disease. Lyons and Benjamin 24 observed that the acute administration of quinapril in humans evaluated by forearm blood flow plethysmography had both a greater inhibition of the vascular ACE and a better improvement of endothelial function than enalapril, an ACE inhibitor with low affinity by tissular ACE. 25 These results were later confirmed by Anderson et al, 26 who showed that patients with coronary artery disease treated with quinapril improved the endothelial function, evaluated by flow mediated dilation. However, subjects who received enalapril or losartan, an antagonist of the receptor AT 1 of angiotensin II, or amlodipine, a calcium channel blocker, did not have the improvement observed in the group treated with quinapril.
ACE plays a major role in the regulation of the vascular tone by converting angiotensin I into the octapeptide angiotensin II, a powerful vasoconstrictor and proliferative of the vascular smooth muscle cells. Interestingly, tissular ACE inactivates the vasodilatory nonapeptide bradykinin. 27 Tissular ACE is much more concentrate that ACE in plasma and has more affinity by bradykinin that with angiotensin I. 27 Bradykinin exerts its vasodilatory action through stimulation of endothelial B2 kinin receptors thereby causing the synthesis and release of prostacyclin, NO and derived hyperpolarising factor. 28 Horning et al 29 demonstrated that quinapril increased the endothelium-dependent vasodilator response to hyperaemia in the radial artery of healthy subjects, an effect that was totally inhibited by icatiban, a specific antagonist of the B 2 kinin receptor. These results demonstrated clearly that endothelial accumulation of bradykinin is critically important for therapeutic actions of ACE inhibitors and confirmed the early observations of Ferreira et al, 30 who discovered these compounds and denominate them as bradykinin potentiating peptides. Moreover, this proposal can explain the differences observed between the ACE inhibitors with low and high affinity by the endothelial ACE in the capacity of reversing ED.
ACE inhibitors also block the activity of endothelial NAD(P)H oxidase, decreasing the production 32 improves the bioavalability of NO, increasing the levels of cGMP and controlling the hypertension of these women. 33 Pre-eclampsia is also a disease characterised by an increased state of oxidative stress. 34 Thus, the blockade of endothelial enzymes, ACE and NAD(P)H oxidase, look like a new and effective therapeutic target in different cardiovascular diseases, by improving the imbalance between NO and O − 2 , so reversing ED. The clinical relevance of recovering ED has been supported by the HOPE study 35 that demonstrated that ramipril, an inhibitor of endothelial ACE, decreased the mortality rate due to acute myocardial infarction, stroke, revascularisation, heart failure, and the new cases of diabetes mellitus, independently of changes in blood pressure.
Conclusions
Endothelium plays a crucial role in the pathogenesis of cardiovascular disease. The imbalance in the synthesis of NO, O − 2 and ONOO − transform to the endothelium in a proathrogenic, protrombotic and vasoconstrictor organ. Drugs that blockade endothelial ACE and NAD(P)H oxidase are a rational approach to improve this imbalance and to recover endothelial function. These drugs appear as a useful measure in preventive cardiology to reduce the current burden of cardiovascular disease.
